Drugs / Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
also known as
CAR-BCMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02215967 | Aug 2014 → Apr 2019 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215967 ↗ |
| Known as | CAR-BCMA | “We conducted the first-in-humans clinical trial, to our knowledge, of T cells expressing a CAR targeting BCMA (CAR-BCMA).” PMID 29812997 ↗ May 2018 |
| Modality | Cell therapy | “T cells can be genetically modified to express chimeric antigen receptors (CARs)” NCT02215967 ↗ |
| Route | Intravenous | “They will get the T cells through the IV in 1 infusion.” NCT02215967 ↗ |